The steps to therapeutic drug monitoring: A structured approach illustrated with imatinib

Détails

Ressource 1Télécharger: The_Steps_to_Therapeutic_Drug_Monitoring_A_Structued Approach Illustrated with Imatinib.pdf (783.86 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_9A25C1CC37D8
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
The steps to therapeutic drug monitoring: A structured approach illustrated with imatinib
Périodique
Frontiers in Pharmacology
Auteur⸱e⸱s
Buclin T., Thoma Y., Widmer N., André P., Guidi M., Csajka C., Decosterd L..A.
ISSN
1663-9812 (Print)
ISSN-L
1663-9812
Statut éditorial
Publié
Date de publication
2020
Peer-reviewed
Oui
Volume
11
Pages
177
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: epublish
Résumé
Pharmacometric methods have hugely benefited from progress in analytical and computer sciences during the past decades, and play nowadays a central role in the clinical development of new medicinal drugs. It is time that these methods translate into patient care through therapeutic drug monitoring (TDM), due to become a mainstay of precision medicine no less than genomic approaches to control variability in drug response and improve the efficacy and safety of treatments. In this review, we make the case for structuring TDM development along five generic questions: 1) Is the concerned drug a candidate to TDM? 2) What is the normal range for the drug's concentration? 3) What is the therapeutic target for the drug's concentration? 4) How to adjust the dosage of the drug to drive concentrations close to target? 5) Does evidence support the usefulness of TDM for this drug? We exemplify this approach through an overview of our development of the TDM of imatinib, the very first targeted anticancer agent. We express our position that a similar story shall apply to other drugs in this class, as well as to a wide range of treatments critical for the control of various life-threatening conditions. Despite hurdles that still jeopardize progress in TDM, there is no doubt that upcoming technological advances will shape and foster many innovative therapeutic monitoring methods.
Mots-clé
drug monitoring, molecular targeted therapies, pharmacokinetic-pharmacodynamic models, pharmacometrics, precision medicine, dosage individualization, TDM, dosage individualization, drug monitoring, molecular targeted therapies, pharmacokinetic-pharmacodynamic models, pharmacometrics, precision medicine
Pubmed
Open Access
Oui
Financement(s)
Fonds national suisse
Création de la notice
10/03/2020 17:54
Dernière modification de la notice
14/07/2020 6:21
Données d'usage